VJHemOnc is committed to improving our service to you

SOHO 2020 | Current treatment landscape for relapsed MCL

VJHemOnc is committed to improving our service to you

Jonathon B. Cohen

Jonathon B. Cohen, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, provides an overview of the current treatment landscape for relapsed mantle-cell lymphoma (MCL) including the use of BTK inhibitors which are effective in relapsed patients but do not induce long-term remission. Dr Cohen also discusses the use of lenalidomide and venetoclax in this indication, as well as CAR T-cell therapies approved for relapsed MCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter